3 Reasons Pfizer Stock Will Crush the Broader Market in 2022

3 Reasons Pfizer Stock Will Crush the Broader Market in 2022
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer (NYSE: PFE) has been the second-best-performing big pharma stock for the whole of 2021. Pfizer's shares have soared this year due to its dominance in the COVID-19 vaccine market, as well as its late-stage trial success with the oral antiviral pill Paxlovid. Despite this sizable jump in 2021, Pfizer seems primed to crush the broader market yet again in 2022.